BR112022005575A2 - Métodos de tratar pênfigo por administração de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrila - Google Patents
Métodos de tratar pênfigo por administração de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilaInfo
- Publication number
- BR112022005575A2 BR112022005575A2 BR112022005575A BR112022005575A BR112022005575A2 BR 112022005575 A2 BR112022005575 A2 BR 112022005575A2 BR 112022005575 A BR112022005575 A BR 112022005575A BR 112022005575 A BR112022005575 A BR 112022005575A BR 112022005575 A2 BR112022005575 A2 BR 112022005575A2
- Authority
- BR
- Brazil
- Prior art keywords
- enonitrile
- oxetan
- pent
- pyrazolo
- piperazin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913029P | 2019-10-09 | 2019-10-09 | |
| US201962942877P | 2019-12-03 | 2019-12-03 | |
| PCT/US2020/054809 WO2021072095A1 (en) | 2019-10-09 | 2020-10-08 | Methods of treating pemphigus by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022005575A2 true BR112022005575A2 (pt) | 2022-06-21 |
Family
ID=73030241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022005575A BR112022005575A2 (pt) | 2019-10-09 | 2020-10-08 | Métodos de tratar pênfigo por administração de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrila |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210106583A1 (https=) |
| EP (1) | EP4041240A1 (https=) |
| JP (2) | JP7784995B2 (https=) |
| KR (1) | KR20220079909A (https=) |
| CN (1) | CN115190798A (https=) |
| AU (1) | AU2020363873A1 (https=) |
| BR (1) | BR112022005575A2 (https=) |
| CA (1) | CA3153750A1 (https=) |
| CO (1) | CO2022005949A2 (https=) |
| IL (1) | IL291726A (https=) |
| MX (1) | MX2022004283A (https=) |
| WO (1) | WO2021072095A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025090703A1 (en) * | 2023-10-25 | 2025-05-01 | Principia Biopharma Inc. | Treatment of chronic spontaneous urticaria by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4- d]pyrimidin-l-yl]piperidine-l-carbonyl]-4-methyl-4-[4-(oxetan-3- yl)piperazin-l-yl]pent-2-enenitrile |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2892900T1 (en) | 2012-09-10 | 2018-01-31 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
| CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
| SG11201704808VA (en) | 2014-12-18 | 2017-07-28 | Principia Biopharma Inc | Treatment of pemphigus |
| PT3236953T (pt) | 2014-12-24 | 2021-01-29 | Principia Biopharma Inc | Dosagem específica de sítio de um inibidor de btk |
| CN115054586B (zh) * | 2016-06-29 | 2024-08-02 | 普林斯匹亚生物制药公司 | 改性的释放制剂 |
| WO2019208805A1 (ja) * | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
-
2020
- 2020-10-08 KR KR1020227015113A patent/KR20220079909A/ko active Pending
- 2020-10-08 JP JP2022520968A patent/JP7784995B2/ja active Active
- 2020-10-08 CA CA3153750A patent/CA3153750A1/en active Pending
- 2020-10-08 BR BR112022005575A patent/BR112022005575A2/pt unknown
- 2020-10-08 US US17/066,300 patent/US20210106583A1/en not_active Abandoned
- 2020-10-08 CN CN202080083113.6A patent/CN115190798A/zh active Pending
- 2020-10-08 EP EP20797943.6A patent/EP4041240A1/en active Pending
- 2020-10-08 AU AU2020363873A patent/AU2020363873A1/en active Pending
- 2020-10-08 WO PCT/US2020/054809 patent/WO2021072095A1/en not_active Ceased
- 2020-10-08 MX MX2022004283A patent/MX2022004283A/es unknown
-
2022
- 2022-03-27 IL IL291726A patent/IL291726A/en unknown
- 2022-05-06 CO CONC2022/0005949A patent/CO2022005949A2/es unknown
- 2022-09-30 US US17/957,073 patent/US20230158033A1/en active Pending
-
2025
- 2025-07-18 JP JP2025120944A patent/JP2025157438A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4041240A1 (en) | 2022-08-17 |
| KR20220079909A (ko) | 2022-06-14 |
| US20230158033A1 (en) | 2023-05-25 |
| MX2022004283A (es) | 2022-07-12 |
| CA3153750A1 (en) | 2021-04-15 |
| CN115190798A (zh) | 2022-10-14 |
| CO2022005949A2 (es) | 2022-07-29 |
| JP2025157438A (ja) | 2025-10-15 |
| IL291726A (en) | 2022-05-01 |
| JP2022552199A (ja) | 2022-12-15 |
| JP7784995B2 (ja) | 2025-12-12 |
| TW202128172A (zh) | 2021-08-01 |
| US20210106583A1 (en) | 2021-04-15 |
| AU2020363873A1 (en) | 2022-04-14 |
| WO2021072095A1 (en) | 2021-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200315B1 (ar) | مركبات بورينون واستخدامها في معالجة السرطان | |
| MX2021007970A (es) | Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo. | |
| CY1125772T1 (el) | Μακροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νοσων | |
| ZA202202361B (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| MY198928A (en) | B7-h3 antibody, antigen-binding fragment thereof and medical use thereof | |
| EA201892075A1 (ru) | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей | |
| MX390627B (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| PH12018500762A1 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112021024886A2 (pt) | Métodos de tratar a doença de fabry em pacientes com insuficiência renal | |
| EP4279127A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| BR112018069930A2 (pt) | agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| EA202190744A1 (ru) | Слитый белок glp1-fc и его конъюгат | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| MX390667B (es) | Dosis y regimen para un inhibidor de la interaccion de hdm2-p53 en tumores hematologicos. | |
| BR112018008769A2 (pt) | formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída | |
| BR112022005575A2 (pt) | Métodos de tratar pênfigo por administração de (r)-2-[3-[4-amino-3-(2-fluoro-4-fenóxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrila | |
| BR112022009881A2 (pt) | Inibidores de caspase 6 e usos dos mesmos | |
| EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ | |
| EA202193041A1 (ru) | Многослойные фармацевтические или нутрицевтические твердые лекарственные формы, содержащие производные пиримидина и/или пурина и витамины в, их получение и применение | |
| CL2022003477A1 (es) | Compuesto de alquenilpirimidina, método de preparación del mismo y aplicación del mismo | |
| MX2019005572A (es) | Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |